Envigo Appoints Patricia Henahan as New Chief Financial Officer
News Jun 11, 2016
Envigo announced that it has appointed Patricia Henahan to the position of Chief Financial Officer. Ms. Henahan has extensive financial experience in the life sciences sector, including leadership roles at Eli Lilly, AstraZeneca, MedImmune and Hospira. She has strong expertise in financial analysis, strategic planning, R&D and operations, with a history of driving continuous improvement through the teams she has led.
"I am delighted that Pat has decided to join the team at Envigo," said Brian Cass, Chief Executive Officer. "Her background in pharmaceuticals and experience across the R&D process will bring valuable insight to our strategic planning as we continue to position Envigo as a leading provider of contract services and research models globally."
Prior to joining Envigo, Ms Henahan was Vice President of Finance for Hospira’s $3 billion US pharmaceutical business and was a key member of the executive team delivering double digit profit growth during her time there. Previous to that she was Chief Financial Officer of the AstraZeneca Group company IPR Pharmaceuticals. Ms Henahan also served for 10 years as a US Army Captain in the Medical Corps.
Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania, a bachelor's degree in Biology from the University of Notre Dame, and is a Six Sigma Black Belt.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018